Inhibition of fatty acid synthase with FT-4101 safely reduces hepatic de novo lipogenesis and steatosis in obese subjects with non-alcoholic fatty liver disease: Results from two early-phase randomized trials
by Cyrus Huneycutt | Nov 26, 2023 | 0 comments


Recent Comments